The US Food and Drug Administration’s tentative approval process and the global fight against HIV
This paper was originally published by Harinder Singh Chahal, Jeffrey S Murray, Martin Shimer, Peter Capella, Ryan Presto, Mary Lou Valdez, […]
This paper was originally published by Harinder Singh Chahal, Jeffrey S Murray, Martin Shimer, Peter Capella, Ryan Presto, Mary Lou Valdez, […]
This paper was originally published by J. Javier Hernandez, Michael Pryszlak, Lindsay Smith, Connor Yanchus, Naheed Kurji, Vijay M. Shahani and
Litigation related to drug patents, whether it be direct patent challenges, contract disputes, or other cases, can provide direct intelligence
Disclosure: the majority of the companies mentioned below are, or have been, clients of DrugPatentWatch Drug patent litigation can be
Pharmacists, as the interface between the general public and prescription drug manufacturers, can sometimes feel as if they’re treading a
How Pharmacists Are Trapped in the Middle of Drug Price Wars Read Post »
Which Company Will be the First to Launch a Generic Drug? There are many reasons to find out which companies
How to Use Tentative Drug Approvals to Anticipate Generic Entry Read Post »
This paper was originally published by Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn,
This paper was originally published by Martin Schiestl, Markus Zabransky, and Fritz Sörgel in Drug Des Devel Ther. 2017; 11: 1509–1515 under
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways Read Post »
What can we build for you? Do you have special business intelligence needs? Let us apply our industry expertise and
Make better decisions with advanced biopharmaceutical business intelligence Read Post »
Subscribe to our weekly newsletter below and never miss the latest product or an exclusive offer.